文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

体外心肺复苏与常规心肺复苏在成人心脏骤停中的比较:比较荟萃分析与试验序贯分析

Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with cardiac arrest: a comparative meta-analysis and trial sequential analysis.
PubMed 文献 · Lancet Respir Med · 2023-05-22
一句话结论与常规心肺复苏相比,体外心肺复苏(ECPR)可降低成人心脏骤停院内死亡率并改善神经预后与生存,尤其对院内心脏骤停患者,作者认为可考虑用于符合条件的IHCA患者。

该研究为系统评价与荟萃分析,检索2000年1月1日至2023年4月1日MEDLINE、Embase和Scopus,纳入11项比较ECPR与常规心肺复苏(CCPR)的随机对照试验和倾向评分匹配研究,共4595例接受ECPR和4597例接受CCPR的成人(≥18岁)院外心脏骤停(OHCA)和院内心脏骤停(IHCA)患者。主要终点为院内死亡率。ECPR与院内死亡率显著降低相关(OR 0.67,95%CI 0.51-0.87;p=0.0034;高确定性),IHCA亚组院内死亡率更低(OR 0.42,95%CI 0.25-0.70;p=0.0009),OHCA亚组无差异(OR 0.76,95%CI 0.54-1.07;p=0.12)。ECPR还与短期和长期神经预后良好生存率增加相关,以及30天、3个月、6个月和1年生存率增加。中心容量与死亡率降低相关(中心容量每翻倍回归系数-0.17,95%CI -0.32至-0.017;p=0.030)。作者认为ECPR可考虑用于符合条件的IHCA患者,但OHCA患者需进一步研究。

要点

  • 纳入11项研究共4595例ECPR和4597例CCPR成人心脏骤停患者,ECPR与院内死亡率降低相关(OR 0.67,95%CI 0.51-0.87;p=0.0034;高确定性)。
  • IHCA亚组接受ECPR者院内死亡率低于CCPR(OR 0.42,95%CI 0.25-0.70;p=0.0009),OHCA亚组无差异(OR 0.76,95%CI 0.54-1.07;p=0.12)。
  • ECPR与短期(OR 1.65,95%CI 1.02-2.68;p=0.042;中等确定性)和长期(OR 2.04,95%CI 1.41-2.94;p=0.0001;高确定性)神经预后良好生存率增加相关。
  • ECPR组30天(OR 1.45,95%CI 1.08-1.96;p=0.015)、3个月(OR 3.98,95%CI 1.12-14.16;p=0.033)、6个月(OR 1.87,95%CI 1.36-2.57;p=0.0001)和1年(OR 1.72,95%CI 1.52-1.95;p<0.0001)生存率均增加。
  • 中心容量(各中心每年ECPR运行例数)与死亡率降低相关(每翻倍回归系数-0.17,95%CI -0.32至-0.017;p=0.030)。

适用人群与场景

  • 成人(年龄≥18岁)院外心脏骤停(OHCA)和院内心脏骤停(IHCA)患者,比较ECPR与常规心肺复苏(CCPR)。

研究设计与关键结果

  • 系统评价与荟萃分析,检索MEDLINE(via PubMed)、Embase和Scopus从2000年1月1日至2023年4月1日,纳入随机对照试验和倾向评分匹配研究,共11项研究、4595例接受ECPR和4597例接受CCPR的患者。
  • 主要终点院内死亡率:ECPR与总体院内死亡率显著降低相关(OR 0.67,95%CI 0.51-0.87;p=0.0034;高确定性),无发表偏倚证据(pegger=0.19),试验序贯分析与荟萃分析一致。
  • IHCA亚组院内死亡率ECPR低于CCPR(OR 0.42,95%CI 0.25-0.70;p=0.0009);OHCA亚组无差异(OR 0.76,95%CI 0.54-1.07;p=0.12)。
  • 中心容量(各中心每年ECPR运行例数)与死亡率降低相关(中心容量每翻倍回归系数-0.17,95%CI -0.32至-0.017;p=0.030)。
  • ECPR与短期(出院至心脏骤停后30天)神经预后良好生存率增加相关(OR 1.65,95%CI 1.02-2.68;p=0.042;中等确定性),与长期(心脏骤停后≥90天)神经预后良好生存率增加相关(OR 2.04,95%CI 1.41-2.94;p=0.0001;高确定性)。
  • ECPR组30天生存率增加(OR 1.45,95%CI 1.08-1.96;p=0.015),3个月生存率增加(OR 3.98,95%CI 1.12-14.16;p=0.033),6个月生存率增加(OR 1.87,95%CI 1.36-2.57;p=0.0001),1年生存率增加(OR 1.72,95%CI 1.52-1.95;p<0.0001)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入随机对照试验和倾向评分匹配研究;使用GRADE方法评级证据确定性,随机对照试验偏倚风险用Cochrane risk-of-bias 2.0工具评估,观察性研究用Newcastle-Ottawa量表评估。
  • 主要终点院内死亡率为高确定性证据;短期神经预后良好生存率为中等确定性证据;长期神经预后良好生存率为高确定性证据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与CCPR相比,ECPR可降低院内死亡率并改善长期神经预后和心脏骤停后生存,尤其对IHCA患者,ECPR可考虑用于符合条件的IHCA患者,但OHCA患者需进一步研究。
  • 中心容量(各中心每年ECPR运行例数)与死亡率降低相关(每翻倍回归系数-0.17,95%CI -0.32至-0.017;p=0.030)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although outcomes of patients after cardiac arrest remain poor, studies have suggested that extracorporeal cardiopulmonary resuscitation (ECPR) might improve survival and neurological outcomes. We aimed to investigate any potential benefits of using ECPR over conventional cardiopulmonary resuscitation (CCPR) in patients with out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA).

METHODS: In this systematic review and meta-analysis, we searched MEDLINE via PubMed, Embase, and Scopus from Jan 1, 2000, to April 1, 2023, for randomised controlled trials and propensity-score matched studies. We included studies comparing ECPR with CCPR in adults (aged ≥18 years) with OHCA and IHCA. We extracted data from published reports using a prespecified data extraction form. We did random-effects (Mantel-Haenszel) meta-analyses and rated the certainty of evidence using the Grading of Recommendations, Assessments, Developments, and Evaluations (GRADE) approach. We rated the risk of bias of randomised controlled trials using the Cochrane risk-of-bias 2.0 tool, and that of observational studies using the Newcastle-Ottawa Scale. The primary outcome was in-hospital mortality. Secondary outcomes included complications during extracorporeal membrane oxygenation, short-term (from hospital discharge to 30 days after cardiac arrest) and long-term (≥90 days after cardiac arrest) survival with favourable neurological outcomes (defined as cerebral performance category scores 1 or 2), and survival at 30 days, 3 months, 6 months, and 1 year after cardiac arrest. We also did trial sequential analyses to evaluate the required information sizes in the meta-analyses to detect clinically relevant reductions in mortality.

FINDINGS: We included 11 studies (4595 patients receiving ECPR and 4597 patients receiving CCPR) in the meta-analysis. ECPR was associated with a significant reduction in overall in-hospital mortality (OR 0·67, 95% CI 0·51-0·87; p=0·0034; high certainty), without evidence of publication bias (pegger=0·19); the trial sequential analysis was concordant with the meta-analysis. When considering IHCA only, in-hospital mortality was lower in patients receiving ECPR than in those receiving CCPR (0·42, 0·25-0·70; p=0·0009), whereas when considering OHCA only, no differences were found (0·76, 0·54-1·07; p=0·12). Centre volume (ie, the number of ECPR runs done per year in each centre) was associated with reductions in odds of mortality (regression coefficient per doubling of centre volume -0·17, 95% CI -0·32 to -0·017; p=0·030). ECPR was also associated with an increased rate of short-term (OR 1·65, 95% CI 1·02-2·68; p=0·042; moderate certainty) and long-term (2·04, 1·41-2·94; p=0·0001; high certainty) survival with favourable neurological outcomes. Additionally, patients receiving ECPR had increased survival at 30-day (OR 1·45, 95% CI 1·08-1·96; p=0·015), 3-month (3·98, 1·12-14·16; p=0·033), 6-month (1·87, 1·36-2·57; p=0·0001), and 1-year (1·72, 1·52-1·95; p<0·0001) follow-ups.

INTERPRETATION: Compared with CCPR, ECPR reduced in-hospital mortality and improved long-term neurological outcomes and post-arrest survival, particularly in patients with IHCA. These findings suggest that ECPR could be considered for eligible patients with IHCA, although further research into patients with OHCA is warranted.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Low CJW, Ramanathan K, Ling RR, et al. Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with cardiac arrest: a comparative meta-analysis and trial sequential analysis. Lancet Respir Med. 2023. PMID: 37230097. doi:10.1016/S2213-2600(23)00137-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。